|
| Desirable characteristics of growth factor-eluting scaffolds (adapted from [24]) | |
|
| Low immunogenic and antigenic response. | |
| Controllable breakdown into benign biodegradable products occurring contemporaneously with new bone formation. | |
| Good mechanical properties during breakdown, while retaining a porous structure capable of cellular infiltration | |
| Good “biocompatibility”*. | |
| Ability to load a growth factor with high efficiency and elute a therapeutical dosage over a sustained period of time relevant to the application. | |
| Ability to be readily sterilised without either loss of mechanical function or denaturation of delivered drug. | |
| Adaptability to wound site, surgical malleability. | |
| Relatively long shelf-life, allowing for ease of access to a surgeon. | |
|